| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| IL2-H5210 | Human | ActiveMax® Human IL-12 Protein,Tag Free (MALS verified) |  |
|
|
| IL2-H8210 | Human | Biotinylated Human IL-12B&IL-12A Heterodimer Protein, His,Avitag™&Flag Tag |  |
|
|
| IL2-H4210 | Human | Human IL-12B&IL-12A Heterodimer Protein, His Tag&Flag Tag |  |
|
|
Human IL-12 R beta 1, Fc Tag (Cat. No. ILB-H5255) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human IL-12B&IL-12A Heterodimer Protein, His Tag&Flag Tag (Cat. No. IL2-H4210) with an affinity constant of 2.06 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Thalidomide | NSC-66847; NSC-527179; K-17; VP-02 | Approved | Celgene Corp | Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled | Japan | Leprosy, Lepromatous | Fujimoto Pharmaceutical | 1982-01-01 | Waldenstrom Macroglobulinemia; Sarcoma; Prostatic Neoplasms; Arachnoiditis; Cholangitis, Sclerosing; Gastrointestinal Hemorrhage; Osteosarcoma; Pancreatitis, Chronic; Retinoblastoma; Sarcoma, Ewing; Lymphoma, Mantle-Cell; Prostatitis; Colitis, Ulcerative; Colorectal Neoplasms; Neuroectodermal Tumors, Primitive; Erythema Nodosum; Leprosy, Lepromatous; Endometrial Neoplasms; Appendiceal Neoplasms; Pelvic Pain; Angiodysplasia; Glioma; Lymphoma, Non-Hodgkin; Carcinoma, Hepatocellular; Amyotrophic Lateral Sclerosis; Vascular Malformations; Crohn Disease; Precancerous Conditions; Mycobacterium avium-intracellulare Infection; Idiopathic Pulmonary Fibrosis; Leukemia; Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Liver Neoplasms; Cough; Telangiectasia, Hereditary Hemorrhagic; Mycobacterium Infections; Rhabdomyosarcoma; Arteriovenous Malformations; Inflammatory Bowel Diseases; Stomatitis, Aphthous; Gastric Antral Vascular Ectasia; Spondylitis, Ankylosing; Myelodysplastic Syndromes; HIV Infections; Coronavirus Dise | Details |
| Ustekinumab | CNTO-1275; C-340; AVT-04 | Approved | Janssen Global Services Llc | Stelara | Mainland China | Plaque psoriasis | Janssen-Cilag International Nv | 2009-01-15 | Multiple Sclerosis; Dermatitis, Atopic; Plaque psoriasis; Crohn Disease; Hidradenitis Suppurativa; Colitis, Ulcerative; Pemphigoid, Bullous; Arthritis, Psoriatic; Takayasu Arteritis; Lupus Erythematosus, Systemic; Psoriasis; Diabetes Mellitus, Type 1; Arthritis, Juvenile; Sjogren's Syndrome; Ichthyosis; Pouchitis; Spondylitis, Ankylosing; Inflammatory Bowel Diseases; Dermatomyositis; Polymyositis; Liver Cirrhosis, Biliary; Solid tumours | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Ustekinumab Biosimilar (NeuClone/Serum Institute of India) | Phase 1 Clinical | Neuclone, Serum Institute Of India | Autoimmune Diseases | Details | |
| EGFR IL12 CART | Phase 1 Clinical | Shenzhen Prekin Biopharmaceutical Co Ltd | Colorectal Neoplasms | Details | |
| Ustekinumab biosimilar(CSPC Pharma) | Phase 1 Clinical | Jushi Biopharmaceutical Co Ltd | Plaque psoriasis | Details | |
| VG-201 | VG-201 | Phase 1 Clinical | ViroGin Biotech Ltd | Esophageal Neoplasms; Stomach Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| ABOD-2011 | ABOD-2011 | Phase 1 Clinical | Cancer Hospital Of Chinese Academy Of Medical Sciences | Solid tumours | Details |
| Ustekinumab biosimilar(DM Bio) | DA-3115; DMB-3115 | Meiji Seika Pharma Co Ltd, Dong-A Pharmaceutical Co Ltd | Details | ||
| Recombinant Human IL12/15-PDL1B Herpes Simplex Type I Oncolytic Virus(CNBG) | VG-161 | Phase 2 Clinical | Liver Neoplasms; Solid tumours; Biliary Tract Neoplasms; Esophageal Neoplasms; Neoplasms | Details | |
| Ustekinumab biosimilar(Amgen) | ABP-654 | Amgen Inc | Details | ||
| Ustekinumab biosimilar (BioFactura) | BFI-751 | BioFactura Australia Pty Ltd | Details | ||
| MEDI-1191 | MEDI-1191; MEDI1191 | Moderna Inc | Details | ||
| Mycobacterium cell wall-DNA Complex (ProMetic Life Sciences) | EN-3348 | Prometic Life Sciences | Details | ||
| GX-51 | GX-051 | Pocastem, Genexine Inc | Details | ||
| Briakinumab | J-695; ABT-874; LU-415977; A-796874.0; BSF-415977; WAY-165772 | Cambridge Antibody Technology | Details | ||
| Interleukin-12 gene therapy (OncoSec Medical) | pIL-12; DNA IL-12 | Inovio | Details | ||
| IL-12 gene therapy (Methodist Hospital) | Methodist Hospital System | Details | |||
| ONCR-177 | ONCR-177 | Oncorus | Details | ||
| NSC-733972 | M-032; M032-H SV-1; NSC-733972 | University Of Alabama At Birmingham | Details | ||
| MEDI-9253 | Phase 1 Clinical | Astrazeneca Pharmaceutical Co Ltd | Solid tumours; Neoplasms | Details | |
| DF-6002 | DF-6002 | Phase 2 Clinical | Dragonfly Therapeutics | Solid tumours; Neoplasms | Details |
| NHS-IL-12 | M-9241; MSB-0010360 | National Cancer Institute, Emd Serono Inc, Merck Serono | Details | ||
| Rocakinogene sifuplasmid | INO-9012 | Phase 2 Clinical | Inovio | Neoplasms, Glandular and Epithelial; Precancerous Conditions; Carcinoma, Hepatocellular; Vulvar Diseases; Lung Neoplasms; Hepatitis C; Colorectal Neoplasms; Squamous Intraepithelial Lesions of the Cervix; Lymphoma, Mantle-Cell; Breast Neoplasms; Prostatic Neoplasms; Carcinoma, Transitional Cell; Hepatitis, Chronic; Papillomavirus Infections; Pancreatic Neoplasms; Urogenital Abnormalities; Glioblastoma; Esophageal Neoplasms; Stomach Neoplasms; HIV Infections; Ovarian Neoplasms; Head and Neck Neoplasms; Liver Neoplasms | Details |
| Ustekinumab biosimilar(Formycon) | FYB-202 | Phase 3 Clinical | Formycon | Psoriasis | Details |
| Apilimod mesilate | STA-5326-mesylate; LAM-002; LAM-002A; STA-5326; AIT-101 | Phase 2 Clinical | Lam, Synta | Coronavirus Disease 2019 (COVID-19); Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin; Crohn Disease; Amyotrophic Lateral Sclerosis; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| Ustekinumab biosimilar (Bio-Thera ) | BAT-2206 | Phase 3 Clinical | Bio-Thera Solutions Ltd | Autoimmune Diseases; Psoriasis; Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Plaque psoriasis | Details |
| Ustekinumab Biosimilar (qyuns) | QX-001-S; HDM-3001; QX-001S | Phase 3 Clinical | Qyuns Therapeutics Co Ltd | Psoriasis; Plaque psoriasis | Details |
| T3011 | MVR-T3011; T3011; MVR-T3011 IT; MVR-T3011 IV | Phase 2 Clinical | Immvira Co Ltd | Liver Neoplasms; Solid tumours; Head and Neck Neoplasms; Esophageal Neoplasms; Mesothelioma; Breast Neoplasms; Lung Neoplasms; Lymphoma; Neoplasm Metastasis; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| Lisofylline | BL-194; CT-1501R; A-802710 | Phase 3 Clinical | Cti Biopharma Corp | Diabetes Mellitus, Type 1; Rejection of organ transplantation | Details |
| JCXH-211 | JCXH-211 | Phase 1 Clinical | Jiachen Xihai(Hangzhou)Biotechnology Co Ltd | Solid tumours | Details |
| INO-9112 | INO-9112 | Phase 1 Clinical | Inovio Pharmaceuticals | Hepatitis B; Coronavirus Infections | Details |
| MVR-C5252 | C-5252; MVR-C5252 | Phase 1 Clinical | Immvira Co Ltd | Solid tumours; Glioblastoma; Ganglioglioma; Brain Neoplasms | Details |
This web search service is supported by Google Inc.
A-Z
FLAG
Star Staining
ViruStop
Aneuro
ComboX
ActiveMax
GENPower
ClinMax 
